Additional Study Information: This is a research study for patients that have uterine or ovarian, fallopian tube or primary peritoneal cancer that has come back after the last round of treatment, and whose tumor has tested positive for folate receptor-alpha (FR). An experimental study drug called IMGN151 is being studied as a possible study treatment for endometrial, ovarian, fallopian tube or primary peritoneal cancer. This study is the first time IMGN151 is being given to humans to be tested as a possible treatment for cancer. The purposes of this study are: To determine if IMGN151 an experimental drug made by the Sponsor, is effective at managing these types of cancer. The term experimental means that IMGN151 has not been approved by any Health Authority that regulates new medicines. To find out what effects, both good and/or bad, IMGN151 may have on participants and endometrial, ovarian, fallopian tube or primary peritoneal cancer when given with and following treatment with carboplatin. The study drug is called an antibody drug conjugate (ADC). An ADC is an antibody with an anti-cancer drug attached. The antibody portion of the ADC brings the anticancer drug to the cancer cell. Cancer cells can make proteins not usually made by normal cells. One of these kinds of proteins is called folate receptor alpha (FR). IMGN151 is designed to bind to FR and release the anti-cancer drug inside the cancer cells possibly leading to cell death of those cells that internalize the ADC and those around them. This targeted delivery may help keep the anticancer drug from hurting normal cells.